RayzeBio is a pioneering company in the field of radiopharmaceutical therapeutics, focusing on the development of targeted drugs that utilize radioisotopes to combat cancer. Their approach is built on a century of experience in radiation therapy, delivering radioisotopes directly to solid tumors through intravenous administration. This targeted delivery aims to selectively kill cancer cells, including those in metastatic disease. RayzeBio has established a diverse pipeline of drug candidates, advancing them through rigorous preclinical evaluations and early human imaging studies to inform patient selection and clinical development strategies.

The company operates a state-of-the-art 28,000 square foot research facility in San Diego, which supports their innovative drug discovery efforts. This facility is equipped with advanced capabilities, including a radiochemistry labeling lab for alpha and beta radioisotopes, a vivarium for molecular imaging and biodistribution analysis, and a suite for drug metabolism and pharmacokinetics (DMPK). RayzeBio employs a systematic, data-driven workflow that has enabled them to conduct over 500 in vivo experiments, allowing for the identification of key attributes essential for the development of novel radiopharmaceutical drug candidates. Their iterative process involves in vitro screening, X-ray crystallography, and optimization of linkers and radiolabeling, ensuring a robust approach to drug discovery in the fight against cancer.

United States

Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets

RayzeBio

Company Details